Nerviano Medical Sciences’ presentation from the 8th Annual DDR Inhibitors Summit is now available

We’re thrilled to share the presentation delivered by Lisa Mahnke, MD, PhD, CEO/President, Nerviano Medical Sciences, Inc; CMO, Nerviano Medical Sciences, Srl, Guest Speaker at the recent 8th Annual DDR Inhibitors Summit. Lisa’s presentation “Exploring Next-Gen PARP Inhibitors without PARP Trapping” focused on preclinical features and preliminary clinical data of the highly unique non-trapping, PARP1 […]
Nerviano Medical Sciences is presenting at the 8th Annual DDR Inhibitors Summit

We are excited to announce that Lisa Mahnke, MD, PhD, CEO/President, Nerviano Medical Sciences, Inc; CMO, Nerviano Medical Sciences, Srl, will participate as a Guest Speaker at the 8th Annual DDR Inhibitors Summit taking place in Boston from January 28-30. Lisa’s presentation Exploring Next-Gen PARP Inhibitors without PARP Trapping, scheduled for January 30th at 3:45 […]
Nerviano Medical Sciences announces FDA clearance of two INDs for its PARP1-selective, non-trapping inhibitor NMS-293 to start clinical studies in small cell lung cancer and BRCA wild-type ovarian carcinoma

Nerviano Medical Sciences announces FDA clearance of two INDs for its PARP1-selective, non-trapping inhibitor NMS-293 to start clinical studies in small cell lung cancer and BRCA wild-type ovarian carcinoma NERVIANO, Italy and BOSTON, Mass.,13 January 2025 – Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., […]
Nerviano Medical Sciences S.r.l. Announces the Launch of a New Clinical Trial to Evaluate NMS-153 in Combination with Atezolizumab and Clinical Trial Supply Agreement with Roche

Nerviano Medical Sciences S.r.l. Announces the Launch of a New Clinical Trial to Evaluate NMS-153 in Combination with Atezolizumab and Clinical Trial Supply Agreement with Roche NMS-153: A clinical-stage, potent and highly selective small molecule inhibitor of Monopolar Spindle 1 (MPS1), and cGAS/STING pathway activator, with differentiated mechanism of action and potential for First-in-Class/Best-in-Class The […]
Nerviano Medical Sciences (NMS) to Reacquire World-Wide Rights of NMS-293, a Potent, Highly Selective, Non-Trapping, Brain-Penetrant PARP1 Inhibitor with Promising Clinical Results

Nerviano Medical Sciences (NMS) to Reacquire World-Wide Rights of NMS-293, a Potent, Highly Selective, Non-Trapping, Brain-Penetrant PARP1 Inhibitor with Promising Clinical Results Agreement reached with Merck KGaA to gain back the full rights of NMS-293 Available clinical data support NMS-293 as an ideal partner for combination with DNA-damaging agents like chemotherapies or ADC payloads: NMS […]
Nerviano Medical Sciences Announces Strategic acquisition of atamparib, a Phase II-ready PARP7 Inhibitor, from Ribon Therapeutics

NERVIANO, Italy and BOSTON, Mass., November 14, 2024 – Nerviano Medical Sciences S.r.l. (NMS) – a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Srl – a global leader in oncological innovation with a leading position in PARP1 inhibitor clinical development in brain cancer, is […]
Nerviano Medical Sciences announces publication of the paper “Present Scenario and Future Landscape of Payloads for ADCs: Focus on DNA-Interacting Agents”

We are pleased to announce the publication of our review article titled “Present Scenario and Future Landscape of Payloads for ADCs: Focus on DNA-Interacting Agents” in Pharmaceuticals, as part of the Special Issue “Evaluation of the Antitumor Mechanism of Armed Antibodies: 2nd Edition“. This paper explores the latest advances in the use of DNA-interacting agents […]
We are speaking at the 15th Annual WADC San Diego 2024!

We are speaking at the 15th Annual WADC 2024 in San Diego . partnering event in San Diego , 4 – 7 Nov. 2024 We look forward to your presence to explore future partnership opportunities. * * * * * Contact: Valsasina Barbara : Barbara.Valsasina@demo111.axxiem.com Lupi Rosita: rosita.lupi@demo111.axxiem.com * * * * * About NMS […]
NMS Group S.p.A. Announces Change in Shareholding Structure, Board of Directors and Statutory Auditors to Accelerate Growth and Innovation

NERVIANO, IT, September 11, 2024 – NMS Group S.p.A. (NMS Group), the largest oncological R&D company in Italy, announces today a change to its shareholding structure, leading to a restructured board of directors and statutory auditors. The Fondazione Regionale per la Ricerca Biomedica (FRRB), established by the Lombardy Regional Government with an aim to promote […]
NMS-UPO paper featured on the cover of Chemistry A European Journal

Turning the Impossible into Reality: A chemical astronaut harnesses blue light irradiation to activate Passerini products containing a Hantzsch ester, derived from what are considered “impossible aldehydes.” Be sure to check out the stunning artwork created by Francesca Brunelli, one of the authors of our latest paper in collaboration with Prof. Professor Tron (Università del […]